Please use this identifier to cite or link to this item:
|Title:||Mitosis-targeted anti-cancer therapies : where they stand||Authors:||Chan, K.-S.
Koh, Cheng Gee.
|Keywords:||DRNTU::Science::Biological sciences||Issue Date:||2012||Source:||Chan, K. S., Koh, C. G., & Li, H. Y. (2012). Mitosis-targeted anti-cancer therapies: where they stand. Cell death and disease, 3(10).||Series/Report no.:||Cell death and disease||Abstract:||The strategy of clinically targeting cancerous cells at their most vulnerable state during mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effective against the abnormal proliferation of transformed cells. Moreover, these antimitotic drugs are also highly selective and sensitive. Despite the robust rate of discovery and the development of mitosis-selective inhibitors, the unpredictable complexities of the human body’s response to these drugs still herald the biggest challenge towards clinical success. Undoubtedly, the need to bridge the gap between promising preclinical trials and effective translational bedside treatment prompts further investigations towards mapping out the mechanistic pathways of MCD, understanding how these drugs work as medicine in the body and more comprehensive target validations. In this review, current antimitotic agents are summarized with particular emphasis on the evaluation of their clinical efficacy as well as their limitations. In addition, we discuss the basis behind the lack of activity of these inhibitors in human trials and the potential and future directions of mitotic anticancer strategies.||URI:||https://hdl.handle.net/10356/99097
|ISSN:||2041-4889||DOI:||http://dx.doi.org/10.1038/cddis.2012.148||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||SBS Journal Articles|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.